List view / Grid view
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
A new analysis reveals that the course of SARS-CoV-2 infection and the immune response it provokes is completely different in adults and children.
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
Binding of SARS-CoV-2 spike proteins to the brain’s endothelial cells can cause the blood-brain barrier to become leaky, potentially causing the neurological symptoms associated with COVID-19.
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
Researchers used flow cytometry to characterise which types of T cells are involved in the immune response to COVID-19 and what they target.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
![A coiling protein 'shell,' called a nucleocapsid, shown here, surrounds Ebola's genetic material, which consists of single-strand RNA. University of Delaware researchers are simulating the way molecules of this nucleocapsid move and interact, atom by atom, to understand their functions and expose targets for anti-viral treatments [Credit: Juan Perilla Laboratory].](https://drug.russellpublishing.co.uk/wp-content/uploads/Ebola-nucleocapsid-e1603365997854.jpg)
Using supercomputer stimulations researchers reveal that the structural stability of the Ebola nucleocapsid is depended on the presence of RNA and interactions with charged ions.
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
